Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, quantification

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87512 refers to the detection of the infectious agent Gardnerella vaginalis through nucleic acid techniques, specifically focusing on the quantification of the organism's DNA or RNA. Gardnerella vaginalis is a bacterium commonly associated with bacterial vaginosis, a condition that affects the female genital tract. This procedure utilizes advanced molecular techniques to identify the presence of Gardnerella vaginalis by measuring the amount of its nucleic acids in a sample. The quantification process is crucial as it not only confirms the presence of the bacteria but also provides valuable information regarding the severity of the infection and the effectiveness of any ongoing treatment. The testing can be performed using various methodologies, including direct probes and amplified probes, with the quantification step being particularly important for assessing the load of the infectious agent. This information is essential for healthcare providers in making informed decisions about patient management and treatment strategies.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure associated with CPT® Code 87512 is indicated for the detection and quantification of Gardnerella vaginalis in patients who may be experiencing symptoms related to bacterial vaginosis. The following conditions may warrant this testing:

  • Bacterial Vaginosis - Patients presenting with symptoms such as abnormal vaginal discharge, odor, itching, or irritation may be tested for Gardnerella vaginalis to confirm the diagnosis of bacterial vaginosis.
  • Monitoring Treatment Response - Quantification of Gardnerella vaginalis can be utilized to assess the effectiveness of treatment in patients diagnosed with bacterial vaginosis, helping to determine if the infection is resolving.
  • Recurrent Infections - Women with a history of recurrent bacterial vaginosis may undergo this test to evaluate the presence and quantity of Gardnerella vaginalis, aiding in the management of their condition.

2. Procedure

The procedure for CPT® Code 87512 involves several key steps to ensure accurate detection and quantification of Gardnerella vaginalis. The following procedural steps are outlined:

  • Sample Collection - A vaginal swab is obtained from the patient to collect a specimen that may contain Gardnerella vaginalis. This sample is critical for the subsequent testing process.
  • Cell Lysis and Nucleic Acid Release - The collected swab is incubated with a lysate solution that ruptures the cells, releasing the nucleic acids present in the sample. This step is essential for isolating the target DNA or RNA from the bacteria.
  • Amplification of Nucleic Acids - In cases where low levels of Gardnerella vaginalis are suspected, an amplification technique, such as polymerase chain reaction (PCR), is employed. This process creates multiple copies of the nucleic acids, enhancing the ability to detect the organism.
  • Quantification - The amplified nucleic acids are then quantified to determine the concentration of Gardnerella vaginalis in the sample. This quantification provides insight into the severity of the infection and helps guide treatment decisions.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 87512, the results of the quantification will be analyzed and reported. Healthcare providers will review the findings to assess the presence and load of Gardnerella vaginalis. Based on the results, further clinical decisions may be made regarding treatment options or additional testing. Patients may be advised on follow-up care, especially if the quantification indicates a significant infection that requires intervention. It is important for healthcare providers to communicate the results clearly to the patient and discuss any necessary next steps in their care plan.

Short Descr GARDNER VAG DNA QUANT
Medium Descr IADNA GARDNERELLA VAGINALIS QUANTIFICATION
Long Descr Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, quantification
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GA Waiver of liability statement issued as required by payer policy, individual case
GV Attending physician not employed or paid under arrangement by the patient's hospice provider
GW Service not related to the hospice patient's terminal condition
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
GZ Item or service expected to be denied as not reasonable and necessary
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2011-01-01 Changed Short description changed.
1998-01-01 Added First appearance in code book in 1998.
Code
Description
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"